Yang Minhui, Hu Changxiao, Cao Yibo, Liang Wanling, Yang Xiangdong, Xiao Tianbao
College of Clinical Medicine, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
Colorectal and Anal Surgery, the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China.
Front Pharmacol. 2021 Jan 19;11:622212. doi: 10.3389/fphar.2020.622212. eCollection 2020.
The biological functions of cyclin B1 (CCNB1) in colon adenocarcinoma (COAD) will be explored in this study. Furthermore, the therapeutic effects and potential molecular mechanisms of ursolic acid (UA) in COAD cells will also be investigated . COAD data were obtained from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. Differentially expressed genes (DEGs) were determined with differential analysis. The biological functions of CCNB1 were analyzed through the GeneCards, the Search Tool for the Retrieval of Interacting Genes (STRING), and the Database for Annotation, Visualization, and Integrated Discovery (DAVID) databases. Therapeutic effects of UA on COAD cell lines HCT-116 and SW-480 were analyzed by CCK-8 and high-content screening (HCS) imaging assay. Flow cytometry was utilized to detect cell cycle changes of SW-480 and HCT-116 cells. Levels of mRNA and expression proteins of HCT-116, SW-480, and normal colon epithelial cells NCM-460 were determined by qRT-PCR and western blot. CCNB1 was highly expressed and acted as an oncogene in COAD patients. CCNB1 and its interacting genes were significantly enriched in the cell cycle pathway. UA effectively inhibited the proliferation and injured COAD cells. In addition, UA arrested cell cycle of COAD cells in S phase. With regard to the molecular mechanisms of UA, we demonstrated that UA can significantly downregulate CCNB1 and its interacting genes and proteins, including CDK1, CDC20, CCND1, and CCNA2, which contributed to cell cycle blocking and COAD treatment. Results from this study revealed that UA possesses therapeutic effects on COAD. The anti-COAD activities of UA are tightly related to suppression of CCNB1 and its interacting targets, which is crucial in abnormal cell cycle process.
本研究将探索细胞周期蛋白B1(CCNB1)在结肠腺癌(COAD)中的生物学功能。此外,还将研究熊果酸(UA)对COAD细胞的治疗效果及潜在分子机制。COAD数据来自基因表达综合数据库(GEO)和癌症基因组图谱(TCGA)数据库。通过差异分析确定差异表达基因(DEG)。通过基因卡片、检索相互作用基因的搜索工具(STRING)和注释、可视化与整合发现数据库(DAVID)分析CCNB1的生物学功能。采用CCK-8和高内涵筛选(HCS)成像分析检测UA对COAD细胞系HCT-116和SW-480的治疗效果。利用流式细胞术检测SW-480和HCT-116细胞的细胞周期变化。通过qRT-PCR和蛋白质免疫印迹法检测HCT-116、SW-480和正常结肠上皮细胞NCM-460的mRNA水平和蛋白表达。CCNB1在COAD患者中高表达并起癌基因作用。CCNB1及其相互作用基因在细胞周期途径中显著富集。UA有效抑制COAD细胞增殖并损伤细胞。此外,UA使COAD细胞的细胞周期停滞在S期。关于UA的分子机制,我们证明UA可显著下调CCNB1及其相互作用基因和蛋白,包括细胞周期蛋白依赖性激酶1(CDK1)、细胞分裂周期蛋白20(CDC20)、细胞周期蛋白D1(CCND1)和细胞周期蛋白A2(CCNA2),这有助于细胞周期阻滞和COAD治疗。本研究结果表明UA对COAD具有治疗作用。UA的抗COAD活性与抑制CCNB1及其相互作用靶点密切相关,这在异常细胞周期过程中至关重要。